Allspring Global Investments Holdings LLC Reduces Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Allspring Global Investments Holdings LLC lessened its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 31.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,705 shares of the specialty pharmaceutical company’s stock after selling 10,702 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Supernus Pharmaceuticals were worth $739,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares during the last quarter. Fidelis Capital Partners LLC purchased a new position in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $33,000. EntryPoint Capital LLC purchased a new position in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $43,000. Meeder Asset Management Inc. purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $47,000. Finally, Innealta Capital LLC purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $51,000.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $33.97 on Friday. Supernus Pharmaceuticals, Inc. has a 1-year low of $23.05 and a 1-year high of $35.56. The company has a market cap of $1.87 billion, a PE ratio of 377.44 and a beta of 0.88. The stock’s 50 day moving average price is $33.02 and its 200 day moving average price is $30.44.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The business had revenue of $168.30 million during the quarter, compared to analysts’ expectations of $148.83 million. During the same quarter last year, the firm earned ($0.02) earnings per share. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. On average, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.